Supplementary Table 2 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
crossref（2024）
Abstract
Supplementary Table 2. Clinical characteristics of patients with HER2 amplified colorectal cancer who received or did not receive anti-HER2 therapy in the DFCI Cohort. All comparisons made using Fisher’s exact test.
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined